DUSA Pharma (DUSA) Posts Q3 Loss of 2c, Beats by 2c
More News related to DUSA
- DUSA Pharma (DUSA) Encouraged By SCC Study to Explore Benefits of Levulan PDT
- Independent Study Utilizing Cyclic Levulan PDT Finds 95 Percent Reduction in New Squamous Cell Carcinoma Lesions in Solid Organ Transplant Recipients Over a 2-Year Period
- DUSA Pharmaceuticals to Present at the Merriman Curhan Ford Investor Summit 2009
- DUSA Pharma (DUSA) Posts Q3 Loss of 2c, Beats by 2c
- DUSA Pharmaceuticals Reports Third Quarter 2009 Corporate Highlights and Financial Results
More News related to Earnings
- Transcept Pharma (TSPT) to Meet with U.S. FDA To Discuss NDA Response Letter for Intermezzo
- DARA BioSciences (DARA) Says Clinical Trial on KRN5500 Achieved Its Primary Endpoint
- Nymox Pharmaceutical (NYMX) Announces Positive Clinical Data on BPH Drug NX-1207
- ARCA Biopharma (ABIO) Annouces Gencaro OK'd by U.S. FDA for Fast Track Program
- Ception and Cephalon (CEPH) Report Initial Results from Phase IIb/III Trial for CINQUIL(TM)
DUSA Pharmaceuticals (NASDAQ: DUSA) reports Q3 loss of $0.02, 2 cents better than the analyst estimate of ($0.04). Revenue for the quarter was $6.20 million, which compares to the estimate of $7.07 million.
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
